Banking on metabolomics for novel therapies in TNBC

Despite sharing the lack of hormone receptors and HER2 amplification used to guide therapeutic decisions,Triple-Negative Breast Cancer(TNBC)is a highly heterogeneous subset of breast cancer.In a recent study published in Cell Research,Xiao et al.highlight the opportunity of using this tumor subtype's metabolic signatures to better stratify patients and identify more effective therapeutic strategies in TNBC.